# Use of Direct Oral Anticoagulants in UK

> **NCT03119116** · — · COMPLETED · sponsor: **Bayer** · enrollment: 31336 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Dabigatran
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT03119116
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-15
- **Primary completion:** 2017-10-16
- **Final completion:** 2019-04-16
- **Target enrollment:** 31336 (ACTUAL)
- **Last updated:** 2020-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03119116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03119116, "Use of Direct Oral Anticoagulants in UK". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03119116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*